Novo Nordisk A/S (B shares) (NOVO-B) — Stock analysis
DKKCurrent price
291,50 DKK
-2,10 DKK (-0.72%) today
Market signals
About Novo Nordisk A/S (B shares)
Novo Nordisk is one of the world's largest pharmaceutical companies, specialising in diabetes and obesity. It is the global leader in GLP-1 drugs (Ozempic/semaglutide for diabetes, Wegovy for obesity), which since 2021 have transformed the company's growth trajectory. Portfolio also includes insulins (Tresiba, NovoRapid), growth hormones and drugs for rare haematological diseases. Founded in 1923 in Bagsværd, Denmark. B shares (NOVO-B) are more liquid; A shares carry more votes. OMX Copenhagen and Euro Stoxx 50 component.
What does Novo Nordisk do?▾
Novo Nordisk is the global leader in diabetes therapies (insulins, GLP-1s like Ozempic) and obesity (Wegovy). GLP-1 drugs based on semaglutide generated a demand boom from 2021. It also operates in rare haematological diseases (haemophilia) and growth hormones.
Which exchange is Novo Nordisk listed on?▾
Novo Nordisk B shares (NOVO-B) are listed on Nasdaq Copenhagen. It is a member of the OMX Copenhagen and Euro Stoxx 50 indexes. It also has ADRs on NYSE as NVO.
Does Novo Nordisk pay dividends?▾
Yes. It pays a growing annual dividend. Yield is typically 1–2%, low due to the rapid share price appreciation driven by the GLP-1 boom.
Analyse this stock with AI
Create a free account and get 2 credits to generate a complete analysis.
Create account · 2 free credits